{"entity":{"id":"nct06948448","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","aka":[],"tldr":"A phase 2 trial of Nivolumab, CAPOX, Bevacizumab in colorectal cancer, run by Ono Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT06948448 by Ono Pharmaceutical Co., Ltd., with 144 participants planned, started 2025-11-18 and due to reach its primary completion in 2028-02-15. Interventions recorded: ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06948448","url":"https://clinicaltrials.gov/study/NCT06948448"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["nivolumab","capox","bevacizumab","flot"],"companies":["deciphera"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06948448","phase":"2","setting":"A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06948448","source":"https://clinicaltrials.gov/study/NCT06948448","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"c64794aebc3663873fafd0e5990e5b730199915e61bae0e3be13dd3ed2fa9e0a","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-16","leadSponsor":"Ono Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":144,"enrolmentType":"ESTIMATED","siteCount":39,"recruitingSiteCount":39,"countries":["Canada","France","Italy","Japan","Spain","United States"]}],"started":"2025-11-18","startedType":"actual","enrolled":144,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06948448/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/"}]}}